Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31, 2026

Pat Growth 25pctRevenue Growth 20pctExceptional ItemAuditor Mid Year ChangeRelated Party TransactionsResults View source PDF

METROPOLIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-5.0%1-day move

₹550.00

prior close

₹600.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-4.3-4.8-5.2-6.2-5.0-7.9-7.7-5.5-4.5-4.3-3.5-4.4+1.3—

Up moveDown movePending

AI summary

Metropolis Healthcare reported strong FY2026 results with consolidated revenue of ₹1,64,585 lakhs, up 23.6% YoY, and standalone revenue of ₹1,36,547 lakhs, up 12.3% YoY. Profit after tax grew 31.4% on consolidated basis to ₹19,118 lakhs, and 26.2% on standalone basis to ₹15,748 lakhs. The company declared a 2nd interim dividend of ₹1 per share and issued bonus shares in 3:1 ratio. Exceptional items of ₹795.67 lakhs (standalone) were recorded due to statutory impact of new Labour Codes. B S R & Co. LLP completed its term and Deloitte Haskins & Sells LLP will be appointed as new statutory auditors. The board also approved appointment of Dr. Nilesh Shah to an advisory role. Ongoing income tax litigation remains a contingent liability with demands reduced to ₹3,880 lakhs after rectification.

Likely market impact

Strong revenue and PAT growth demonstrate solid operational performance. The auditor change and exceptional items warrant attention. Shareholders received dividend and bonus shares, which is positive.